Molecular diagnostics in urologic malignancies a work in progress

George J. Netto

Research output: Contribution to journalArticle

Abstract

Context.-Molecular diagnostic applications are now an integral part of the management algorithms of several solid tumors, such as breast, colon, and lung. In stark contrast, the current clinical management of urologie malignancies is lagging behind. Clinically robust molecular tests that can identify patients who are more likely to respond to a given targeted agent or even those in need of a more aggressive treatment based on well-validated molecular prognosticators are still lacking. Several promising biomarkers for detection, prognosis, and targeted therapeutics are being evaluated. Objective.-To discuss candidate biomarkers that may soon make the transition to clinical assay for patients in urologie oncology. Data Sources.-Selected original articles published in the PubMed service of the US National Library of Medicine. Conclusions.-Recent understanding of the complex molecular alterations involved in the development and progression of urologie malignancies is yielding novel diagnostic and prognostic molecular tools and opening the doors for experimental targeted therapies in these prevalent, frequently lethal solid tumors.

Original languageEnglish (US)
Pages (from-to)610-621
Number of pages12
JournalArchives of Pathology and Laboratory Medicine
Volume135
Issue number5
StatePublished - May 2011

Fingerprint

Molecular Pathology
Neoplasms
Biomarkers
National Library of Medicine (U.S.)
Investigational Therapies
Information Storage and Retrieval
PubMed
Colon
Breast
Lung
Therapeutics

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Molecular diagnostics in urologic malignancies a work in progress. / Netto, George J.

In: Archives of Pathology and Laboratory Medicine, Vol. 135, No. 5, 05.2011, p. 610-621.

Research output: Contribution to journalArticle

@article{980864dae5e6461c8d245f613e4b50c6,
title = "Molecular diagnostics in urologic malignancies a work in progress",
abstract = "Context.-Molecular diagnostic applications are now an integral part of the management algorithms of several solid tumors, such as breast, colon, and lung. In stark contrast, the current clinical management of urologie malignancies is lagging behind. Clinically robust molecular tests that can identify patients who are more likely to respond to a given targeted agent or even those in need of a more aggressive treatment based on well-validated molecular prognosticators are still lacking. Several promising biomarkers for detection, prognosis, and targeted therapeutics are being evaluated. Objective.-To discuss candidate biomarkers that may soon make the transition to clinical assay for patients in urologie oncology. Data Sources.-Selected original articles published in the PubMed service of the US National Library of Medicine. Conclusions.-Recent understanding of the complex molecular alterations involved in the development and progression of urologie malignancies is yielding novel diagnostic and prognostic molecular tools and opening the doors for experimental targeted therapies in these prevalent, frequently lethal solid tumors.",
author = "Netto, {George J.}",
year = "2011",
month = "5",
language = "English (US)",
volume = "135",
pages = "610--621",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "5",

}

TY - JOUR

T1 - Molecular diagnostics in urologic malignancies a work in progress

AU - Netto, George J.

PY - 2011/5

Y1 - 2011/5

N2 - Context.-Molecular diagnostic applications are now an integral part of the management algorithms of several solid tumors, such as breast, colon, and lung. In stark contrast, the current clinical management of urologie malignancies is lagging behind. Clinically robust molecular tests that can identify patients who are more likely to respond to a given targeted agent or even those in need of a more aggressive treatment based on well-validated molecular prognosticators are still lacking. Several promising biomarkers for detection, prognosis, and targeted therapeutics are being evaluated. Objective.-To discuss candidate biomarkers that may soon make the transition to clinical assay for patients in urologie oncology. Data Sources.-Selected original articles published in the PubMed service of the US National Library of Medicine. Conclusions.-Recent understanding of the complex molecular alterations involved in the development and progression of urologie malignancies is yielding novel diagnostic and prognostic molecular tools and opening the doors for experimental targeted therapies in these prevalent, frequently lethal solid tumors.

AB - Context.-Molecular diagnostic applications are now an integral part of the management algorithms of several solid tumors, such as breast, colon, and lung. In stark contrast, the current clinical management of urologie malignancies is lagging behind. Clinically robust molecular tests that can identify patients who are more likely to respond to a given targeted agent or even those in need of a more aggressive treatment based on well-validated molecular prognosticators are still lacking. Several promising biomarkers for detection, prognosis, and targeted therapeutics are being evaluated. Objective.-To discuss candidate biomarkers that may soon make the transition to clinical assay for patients in urologie oncology. Data Sources.-Selected original articles published in the PubMed service of the US National Library of Medicine. Conclusions.-Recent understanding of the complex molecular alterations involved in the development and progression of urologie malignancies is yielding novel diagnostic and prognostic molecular tools and opening the doors for experimental targeted therapies in these prevalent, frequently lethal solid tumors.

UR - http://www.scopus.com/inward/record.url?scp=79956311993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956311993&partnerID=8YFLogxK

M3 - Article

C2 - 21526959

AN - SCOPUS:79956311993

VL - 135

SP - 610

EP - 621

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 5

ER -